CXCL5 and hepatocellular carcinoma: Sorafenib administration led to increased secretion of CXCL5 derived from HCC cells, inhibiting TANs apoptosis by inducing HIF1 α/NF-κB/CXCL5 pathways, enhancing TAN infiltration in both animal models and HCC patients.